These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 2514364)

  • 41. Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).
    Nichols DE; Brewster WK; Johnson MP; Oberlender R; Riggs RM
    J Med Chem; 1990 Feb; 33(2):703-10. PubMed ID: 1967651
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Molecular determinants for recognition of RU 24969 analogs at central 5-hydroxytryptamine recognition sites: use of a bilinear function and substituent volumes to describe steric fit.
    Taylor EW; Nikam SS; Lambert G; Martin AR; Nelson DL
    Mol Pharmacol; 1988 Jul; 34(1):42-53. PubMed ID: 3393140
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues.
    Glennon RA; McKenney JD; Lyon RA; Titeler M
    J Med Chem; 1986 Feb; 29(2):194-9. PubMed ID: 3950904
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ring-substituted amphetamine interactions with neurotransmitter receptor binding sites in human cortex.
    Pierce PA; Peroutka SJ
    Neurosci Lett; 1988 Dec; 95(1-3):208-12. PubMed ID: 2906416
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neurochemical binding profiles of novel indole and benzofuran MDMA analogues.
    Shimshoni JA; Winkler I; Golan E; Nutt D
    Naunyn Schmiedebergs Arch Pharmacol; 2017 Jan; 390(1):15-24. PubMed ID: 27650729
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents.
    Glennon RA; Titeler M; McKenney JD
    Life Sci; 1984 Dec; 35(25):2505-11. PubMed ID: 6513725
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Serotonin and cardiovascular control].
    Aurup P; Højberg S
    Ugeskr Laeger; 1990 Sep; 152(39):2840-3. PubMed ID: 2219514
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 1-(2-Aminoethyl)-3-methyl-8,9-dihydropyrano[3,2-e]indole: a rotationally restricted phenolic analog of the neurotransmitter serotonin and agonist selective for serotonin (5-HT2-type) receptors.
    Macor JE; Fox CB; Johnson C; Koe BK; Lebel LA; Zorn SH
    J Med Chem; 1992 Oct; 35(20):3625-32. PubMed ID: 1433172
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serotonergic receptor subtypes and vascular reactivity.
    Van Nueten JM; Leysen JE; de Clerck F; Vanhoutte PM
    J Cardiovasc Pharmacol; 1984; 6 Suppl 4():S564-74. PubMed ID: 6210424
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines.
    Cozzi NV; Daley PF
    Bioorg Med Chem Lett; 2016 Feb; 26(3):959-964. PubMed ID: 26739781
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The involvement of the 5-HT1 and 5-HT2 receptors and of catecholaminergic systems in different components of the 5-HT syndrome in the rat.
    Rényi L
    Pol J Pharmacol Pharm; 1991; 43(5):405-19. PubMed ID: 1824130
    [No Abstract]   [Full Text] [Related]  

  • 52. Serotonergic properties of spiroxatrine enantiomers.
    Nikam SS; Martin AR; Nelson DL
    J Med Chem; 1988 Oct; 31(10):1965-8. PubMed ID: 2902227
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Relative selectivity of some conformationally constrained tryptamine analogs at 5-HT1, 5-HT1A and 5-HT2 recognition sites.
    Taylor EW; Nikam S; Weck B; Martin A; Nelson D
    Life Sci; 1987 Oct; 41(16):1961-9. PubMed ID: 3657392
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacological profile of novel psychoactive benzofurans.
    Rickli A; Kopf S; Hoener MC; Liechti ME
    Br J Pharmacol; 2015 Jul; 172(13):3412-25. PubMed ID: 25765500
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents.
    Lyon RA; Titeler M; McKenney JD; Magee PS; Glennon RA
    J Med Chem; 1986 May; 29(5):630-4. PubMed ID: 3701781
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pathophysiological relevance of serotonin.
    van Zwieten PA
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S19-25. PubMed ID: 2446063
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison between the neurotoxic and serotonin-depleting effects of various halogenated derivatives of amphetamine in the rat.
    Harvey JA; McMaster SE; Fuller RW
    J Pharmacol Exp Ther; 1977 Sep; 202(3):581-9. PubMed ID: 894522
    [No Abstract]   [Full Text] [Related]  

  • 58. Experimental studies on 3,4-methylenedioxymethamphetamine (MDA, "ecstasy") and its potential to damage brain serotonin neurons.
    Ricaurte GA; McCann UD
    Neurotox Res; 2001 Jan; 3(1):85-99. PubMed ID: 15111263
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Correlation between anorectic potency and affinity for hypothalamic (+)-amphetamine binding sites of phenylethylamines.
    Blosser JC; Barrantes M; Parker RB
    Eur J Pharmacol; 1987 Jan; 134(1):97-103. PubMed ID: 3556402
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phenylalkylamine stimulants, hallucinogens, and designer drugs.
    Glennon RA
    NIDA Res Monogr; 1990; 105():154-60. PubMed ID: 1678860
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.